The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...
With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.
The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...
For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...
Invivyd, Inc. advances VYD2311 as a Covid-19 vaccine alternative. Learn about upcoming trials and market opportunities. Click ...
More than three-quarters of American adults didn’t get a COVID shot last season, a figure that health care experts warn could ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 14, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today ...
Among the most commonly cited reasons for COVID vaccine hesitation are fears about side effects, long-term health ...
2d
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange ...
More than three-quarters of American adults didn't get a covid shot last season, a figure that health care experts warn could rise this year amid new U.S. government recommendations.
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback